Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment

BACKGROUND: To achieve optimal outcomes, an individual approach is needed in the treatment and care of patients. The potential value of tumor mutational burden (TMB) status and/or programmed cell death ligand 1 (PD-L1) expression as biomarkers to predict which patients are most likely to respond to...

Descripción completa

Detalles Bibliográficos
Autores principales: Krieger, Tina, Pearson, Isobel, Bell, Judith, Doherty, Jim, Robbins, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990470/
https://www.ncbi.nlm.nih.gov/pubmed/32000815
http://dx.doi.org/10.1186/s13000-020-0927-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990470/
https://www.ncbi.nlm.nih.gov/pubmed/32000815
http://dx.doi.org/10.1186/s13000-020-0927-9

Ejemplares similares